COVID-19 Treatment Clinic

Spectrum Health currently offers four treatments for confirmed COVID-19 infection. Based on current evidence, oral Paxlovid and intravenous Remdesivir are first-line treatments, while oral Molnupiravir and intravenous Bebtelovimab (a monoclonal antibody) are second-line treatments. Both oral medications must be started within five days of COVID-19 symptoms onset, while intravenous medications must be given within seven days from the symptom onset.

If you have symptoms and test positive for COVID-19, you may either:

Talk to your primary care provider,

or

Call the Spectrum Health Community Response COVID-19 Treatment Clinic. A provider will review your medical history and current medication list to determine eligibility and appropriate treatment.

The decision for treatment is impacted by multiple factors including, but not limited to, your general medical health, duration of symptoms, medications you are taking currently and COVID-19 treatment availability. In addition to the medical criteria for prescription, there are limitations on how many people we can treat; we will prioritize those patients who have the greatest medical need.

Frequently asked questions

How do I know which treatment option is best for me?
close icon

A health care provider will determine if you need a COVID-19 treatment and which mediation is most appropriate for you based on the U.S. Food and Drug Administration Emergency Use Authorization, Michigan Department of Health and Human Services guidelines and your medical history.

If I receive monoclonal antibodies or an oral antiviral medication, can I still get the COVID-19 vaccine?
close icon

Yes, you can get the COVID-19 vaccine, and we encourage you to get vaccinated. When receiving an oral antiviral medication, monoclonal antibodies, or Remdesivir, it is recommended to wait two weeks from initial COVID-19 symptom onset before getting vaccinated or boosted.

Does my quarantine duration change after I receive an infusion or oral antiviral medications?
close icon

No; your quarantine time will remain the same. Despite the anticipated improvement in your symptoms, you will still be contagious. Please continue isolating, wearing a mask, and practicing good handwashing.

COVID-19 treatments under Emergency Use Authorization granted by the U.S. Food and Drug Administration:

  • Bebtelovimab has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high-risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate; and
  • The emergency use of bebtelovimab is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner
  • PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to[1]moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS[1]CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death; and
  • The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID[1]19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb[1]3(b)(1), unless the declaration is terminated or authorization revoked sooner
  • LAGEVRIO (Molnupiravir) has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults who are at high-risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate; and
  • The emergency use of LAGEVRIO is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

Patient stories and news